Patent details
EP4196116 Title: PHARMACEUTICAL COMPOSITION COMPRISING CABOZANTINIB, PLERIXAFOR, AFATINIB AND ETORICOXIB FOR USE IN THE TREATMENT OR PROPHYLAXIS OF NSCLC WITHOUT DRIVER MUTATIONS
Basic Information
- Publication number:
- EP4196116
- PCT Application Number:
- EP2021072486
- Type:
- European Patent Granted for LU
- Legal Status:
- Unitary Effect Registered
- Application number:
- EP217663939
- PCT Publication Number:
- WO2022038038
- First applicant's nationality:
- Translation Language:
- EPO Publication Language:
- English
- English Title of Invention:
- PHARMACEUTICAL COMPOSITION COMPRISING CABOZANTINIB, PLERIXAFOR, AFATINIB AND ETORICOXIB FOR USE IN THE TREATMENT OR PROPHYLAXIS OF NSCLC WITHOUT DRIVER MUTATIONS
- French Title of Invention:
- COMPOSITION PHARMACEUTIQUE COMPRENANT DU CABOZANTINIB, DU PLERIXAFOR, DE L'AFATINIB ET DE L'ÉTORICOXIB POUR UNE UTILISATION DANS LE TRAITEMENT OU LA PROPHYLAXIE DU CPNPC SANS MUTATIONS ONCOGENIQUES
- German Title of Invention:
- PHARMAZEUTISCHE ZUSAMMENSETZUNG, UMFASSEND CABOZANTINIB, PLERIXAFOR, AFATINIB UND ETORICOXIB ZUR VERWENDUNG BEI DER BEHANDLUNG ODER PROPHYLAXE VON NSCLC OHNE DRIVERMUTATIONEN
- SPC Number:
Unitary Effect
- Unitary Effect Requested:
- Yes
- Unitary Effect Request Filing Date:
- 30/07/2024
- Link to UPP Register:
- European Patent Register
- Unitary Effect Request Withdrawal Date:
- Unitary Effect Status:
- Unitary Effect Registered
- Unitary Effect Acceptance Decision Date:
- 23/08/2024
- Unitary Effect Rejection Decision Date:
- Unitary Effect Date:
- 10/07/2024
- Unitary Effect Registration Date:
- 23/08/2024
- Unitary Effect Re-establishment of rights Filing Date:
- Unitary Effect Re-establishment of rights EPO Decision :
- Unitary Effect Re-establishment of rights EPO Decision Date:
- Explanatory Text UE:
- Safety Net Request Date:
- Safety Net Decision Date:
- Safety Net Decision Outcome:
- SPC Number:
Dates
- Filing date:
- 12/08/2021
- Grant date:
- 10/07/2024
- EP Publication Date:
- 21/06/2023
- PCT Publication Date:
- 24/02/2022
- Claims Translation Received Date:
- Translations Received Date (B1 EP Publication):
- Translations Received Date (B2 EP Publication):
- Translations Received Date (B3 EP Publication):
- Publication date:
- 10/07/2024
- EP B1 Publication Date:
- 10/07/2024
- EP B2 Publication Date:
- EP B3 Publication Date:
- Lapsed date:
- Expiration date:
- 12/08/2041
- Renunciation date:
- Revocation date:
- Annulment date:
Owner
- From:
- 03/07/2024
- Name:
- EPO Experimentelle Pharmakologie & Onkologie Berlin-Buch GmbH
- Address:
- Robert-Rössle-Str. 10 Haus 82, 13125 Berlin, Germany (DE)
- Name:
- Langhammer, Stefan
- Address:
- Hirschweg 8, 30938 Burgwedel, Germany (DE)
Inventor
1
- Name:
- LANGHAMMER, STEFAN, Dr.
- Address:
- Germany (DE)
2
- Name:
- GÜRGEN, Dennis
- Address:
- Germany (DE)
3
- Name:
- HOFFMANN, Jens
- Address:
- Germany (DE)
Priority
- Priority Number:
- 102020005002
- Priority Date:
- 17/08/2020
- Priority Country:
- Germany (DE)
Classification
- IPC classification:
- A61K 31/395; A61K 31/444; A61K 31/47; A61K 31/517; A61K 45/06; A61P 35/00;
Publication
European Patent Bulletin
1
- Issue number:
- 202428
- Publication date:
- 10/07/2024
- Description:
- Grant (B1)
2
- Issue number:
- 202436
- Publication date:
- 04/09/2024
- Description:
- Unitary Effect Request Receipt
3
- Issue number:
- 202439
- Publication date:
- 25/09/2024
- Description:
- Unitary Effect Request Acceptance
Annual Fees
- Annual Fee Due Date:
- Annual Fee Number:
- Expected Payer:
- Last Annual Fee Payment Date:
- Last Annual Fee Paid Number:
- Payer:
| Filing date | Document type | Number of pages |
|---|